CAMBRIDGE, Mass., March 11, 2024–(Small business WIRE)–MOMA Therapeutics, a biopharmaceutical organization finding and developing a new technology of precision therapeutics through insights derived from the company’s KnowledgeBase system, right now introduced that Jullian G. Jones, Ph.D., J.D., MBA, has been appointed as the company’s chief company officer. In this part, Dr. Jones will be dependable for guiding MOMA’s company and business enterprise method, which contains trader relations, business enterprise progress, new product or service scheduling, and oversight of strategic finance and accounting.

“We are thrilled to welcome Jullian to MOMA. She has an outstanding track document of pondering and acting strategically and creatively across various business enterprise proportions, though leading with coronary heart and a passion for mentorship,” said Asit Parikh, M.D., Ph.D., main government officer of MOMA. “Jullian’s skills is beautifully aligned with MOMA’s small business desires at this phase of our progress and positions us extra strongly for results. This will be a chaotic yr as we anticipate filing Investigational New Drug applications with the Food and drug administration for our two direct systems.”

A seasoned business enterprise progress govt with additional than 15 several years of life sciences and pharmaceutical business practical experience, Dr. Jones joins MOMA from Monte Rosa Therapeutics, Inc. exactly where she most lately served as main enterprise officer. In that function, she led enterprise development and early professional strategy and competitive insights for portfolio applications and played a pivotal purpose in building the company’s pipeline. Dr. Jones also oversaw the company’s strategic partnership with Roche Pharmaceuticals, as nicely as several collaborations with external associates that increased Monte Rosa’s platform capabilities. Earlier, as SVP, head of business enterprise growth, Dr. Jones’ business enterprise and economical acumen have been integral as a component of the group that direct to Monte Rosa’s upsized IPO in 2021.

“The caliber of MOMA’s science and expertise is unmatched, and I enthusiastically share our collective mission to choose on tough-to-drug, really dynamic proteins at the root of many diseases, such as most cancers,” said Dr. Jones. “I glance forward to collaborating with and studying from MOMA team members across capabilities as we work collectively to progress transformative precision medicines for clients in the in the vicinity of- and very long-term.”

Prior to Monte Rosa, Dr. Jones served as senior director of oncology organization advancement at Eli Lilly and Organization, foremost the identification and strategic evaluation of cross-portfolio in-licensing, out-licensing, and M&A chances for the Oncology Therapeutic Space, including the $8 billion acquisition of Loxo Oncology. Formerly, she served in several leadership roles at Boehringer Ingelheim, together with company advancement and licensing, global marketing, and new merchandise preparing. She commenced her existence sciences company progress vocation at Columbia Know-how Ventures, dependable for licensing early life sciences systems and facilitating the spin-off of early-period businesses. Dr. Jones retains a Ph.D. from Johns Hopkins University, a J.D. from Georgetown University Regulation Center, and an MBA from Colombia College.

About MOMA Therapeutics

MOMA Therapeutics is committed to discovering the upcoming technology of precision medicines by concentrating on very dynamic proteins that underlie human condition. Bringing together seminal scientific breakthroughs in biochemistry, biophysics, structural biology, chemistry, computation, and practical genomics, the organization has founded the KnowledgeBase platform to exploit a key vulnerability inherent to all dynamic proteins: their dependence on properly-coordinated, stepwise improvements in protein conformation. By concentrating this system on disease-leading to targets, MOMA aims to create higher impact, precision medications for individuals with unmet medical needs. MOMA Therapeutics is a non-public organization launched in 2020 with seasoned management, a remarkably specialized workforce with deep knowledge in oncology discovery, earth-course scientific founders, and financed by major biotech buyers.

As portion of its ongoing commitment to precision oncology study and growth, MOMA is also prosecuting two lead plans at enhancement prospect stage, for which it anticipates submitting Investigational New Drug (IND) applications with the U.S. Food stuff and Drug Administration in 2024. These property, alongside with a number of before initiatives, comprise MOMA’s wholly owned portfolio.

View resource model on


Katie Engleman, 1AB
[email protected]